News

Hear about the case, view the slides, and vote on your responses.

Change is an inside job. Are you unhappy with your practice’s growth? Take the often overlooked option of offensive time management. Actively shape your day by establishing what I like to call selective control.

It has been a history-making week for the ophthalmic world, and the FDA approval of the first IOL with extended range of vision (Tecnis Symfony IOL, Abbott) has only added one more reason for celebration.

A portable non-mydriatic fundus camera was found useful in grading cup-to-disc ratio as part of glaucoma screening compared with a standard tabletop mydriatic fundus camera.

A visit to two innovative optical shops reveals differing portraitures of providing better customer experience and increasing capture rate.

Cataract surgery with or without intravenous sedation can be a factor in the clinical experience. Moving to sublingual sedation may be the next step in safety and comfort for a demanding patient demographic.

Delayed patient presentation, compounded by problems relating to insufficient resources and lack of follow-up, explain why pediatric cataract remains an important cause of visual impairment in Tunisia.

The combination of phenylephrine and ketorolac helped maintain pupil diameter and lowered postoperative pain compared with placebo in patients having cataract surgery in two pooled phase III studies.

Surgical draping for ophthalmic surgery has never been quick or easy-until now. A new drape design allows the surgeon or scrub nurse to fully drape the patient in seconds.

The U.S. IDE clinical trial of the investigational extended range of vision IOL (Model ZXR00; Tecnis Symfony Extended Range of Vision IOL, Abbott Medical Optics) found that the implant delivered a full range of uncorrected vision and minimized or eliminated the need for spectacle wear in most patients.

Glaucoma is more likely to develop in children who undergo cataract surgery when they are 6 weeks or younger.

In a multicenter trial including 162 eyes undergoing cataract surgery with implantation of a variety of IOL types, use of intraoperative aberrometry to guide IOL spherical power selection minimized residual refractive error.

Results of two phase III trials with dexamethasone intracanalicular depot are highlighted. Both trials met the endpoints for postsurgical pain, but only one trial met the endpoints for postoperative inflammation

Patients with keratoconus pose unique challenges with IOL calculations.

By just about anybody's definition of success, ophthalmologists are successful: intelligent, well-paid, able to make people’s lives better and held in high esteem by the public. Not to mention good-looking. So they must be happy-right? Not necessarily.

An approach is described for completing cortex removal and IOL implantation after intraoperative 180° zonular dialysis.

Ophthalmologists have been waiting more than a decade for a new treatment option for their dry eye patients-and the anticipation is finally over. Lifitegrast ophthalmic solution 5% (Xiidra, Shire Ophthalmics) is a twice-daily eye drop solution and is the only FDA-approved drug indicated to treat the signs and symptoms of dry eye disease, according to the company.

Watch as Ben Wucher, researcher at University of Rochester Medical Center, summarizes his research titled, "Clinical keratitis isolates of Pseudomonas aeruginosa develop resistant biofilms."

Alcaftadine ophthalmic solution 0.25% was superior to olopatadine hydrochloride ophthalmic solution 0.2% in reducing the itching related to grass and tree pollens in a multicenter, randomized study in subjects with allergic conjunctivitis.

A topical treatment that breaks apart disulfide bonds between crystalline lens proteins was shown to increase accommodative amplitude and improve near visual acuity in a randomized, placebo-controlled clinical trial.

Early results from a repeatability and reproducibility study of a precision ultrasound device indicate the anterior segment imaging device can provide unique measurements on the cornea and will have multiple applications in the future.

Emerging trends and hot topics in eye and vision research filled the sessions at this year’s meeting of the Association for Research in Vision and Ophthalmology.

An advanced, self-validating method is providing a new approach to IOL power selection, explains Warren E. Hill, MD, FACS.

Bausch + Lomb (B + L) outlines the company's commitment to eye care with a strong portfolio, new programs, patient access, and better pricing.

The pace of new glaucoma drug development continues, fueled by continuing research into novel mechanisms of action. Three companies, Aerie Pharmaceuticals, Bausch + Lomb, and Inotek Pharmaceuticals, shared their latest results.

Allergan is moving forward with plans to introduce innovative drug delivery device and surgical device for glaucoma

The laws governing ophthalmic drug and device approvals have changed little in recent years. But the FDA is making significant and far-reaching changes in its approvals process.

Seven glaucoma drug delivery companies reviewed the latest data on platforms